ContraFect : Lysin CF-301 (Exebacase) Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis

Lysin CF-301 (Exebacase) Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis

2ND International Symposium on Antimicrobial Hydrolytic Enzymes

Nov. 6 - 8, 2018

SESSION ONE: GRAM-POSITIVE LYSINS AS THERAPEUTICS

Raymond Schuch, Ph.D.

VP of Research, ContraFect Corporation

Yonkers, NY 10701

http://www.contrafect.com/

©©20162018 ContraFectContraFectCorporationCorporation

CONFIDENTIAL

Forward Looking Statements

This presentation contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believe," "expect," "target", "anticipate," "estimate," "intend," "plan,"

"proposed", "potential" or similar references to future periods. Examples of forward-looking statements in this presentation include statements made regarding ContraFect Corporation's ("ContraFect") therapeutic product candidates, including their ability to treat life-threatening, drug resistant infections, CF-301 properties and activity, in-vitro study results, CF-301 Phase 2 study plans, topline study results, timing of the commencement or completion of clinical trials and patent protection. Forward- looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, proposals, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, the lack of regulatory approval, or the unsuccessful attainment of patent protection. Any forward-looking statement made by ContraFect in this presentation is based only on information currently available and speaks only as of the date on which it is made. No representation or warranty is made as to the completeness or accuracy of the information provided in this presentation. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Audiences are cautioned that forward-looking statements or similar information are not guarantees of future performance and, accordingly, are expressly cautioned not to put undue reliance on forward-looking statements or similar information due to the inherent uncertainty therein.

2	©2016 ContraFect Corporation
© 2018 ContraFect Corporation

CONFIDENTIAL

Background on ContraFect

Lysin platform: novel alternatives to conventional antibiotics

• Bacteriophage-derivedtherapeutic enzymes; potent, targeted and rapidly bactericidal
• Proprietary research and collaborative discovery program with The Rockefeller University
• Portfolio of lysins targeting Gram-positive (and Gram-negative) organisms

Lead program: CF-301 for treatment of Staphylococcus aureus bacteremia

• First and only lysin to enter Ph2 clinical trials in the U.S.
• Fast track status granted by FDA

• Phase 1: Complete - No clinical adverse safety signals observed

• Phase 2: Enrollment completed in 3Q2018

CF-301 studies at ContraFect	Nature	JID
	Aug 2002	May 2014
• In vitro antimicrobial activity (and anti-biofilm activity) of lysin CF-301	Schuch et al.	Schuch et al.

• Efficacy of lysin CF-301 in addition to daptomycin (DAP) or vancomycin (VAN) in a rabbit model of infective endocarditis (IE) due to MRSA
• CF-301may improve clinical outcomes in patients with biofilm-associated infections, such as infective endocarditis

3	2018 ContraFect Corporation
©2016 ContraFect Corporation

CONFIDENTIAL

CF-301 Overview: Hallmark Properties

• Novel MOA: peptidoglycan hydrolysis and osmotic lysis

•	Modular protein design	Lysin:

• Potent and rapidly bactericidal activity
• Targeted killing (species specificity)
• Eradicates biofilms
• • Kills persisters and SCVs
• Synergy with antibiotics
• Extended postantibiotic effect
• Low propensity for resistance
• Suppresses antibiotic resistance

Peptidoglycan
subunit
NAM	NAG
L-Ala
D-Glu
DAP	D-Ala
D-Ala	DAP
	D-Glu
	L-Ala
NAG	NAM
	n
= cleaved by CF-301

4	2018 ContraFect Corporation
©2016 ContraFect Corporation

CONFIDENTIAL

CF-301: Potentiation of Activity in Blood

During development of an AST method to support clinical trials, we observed far more potentactivity in human blood matrices compared to standard AST media (i.e., caMHB):

• The activity of CF-301 in caMHB does not reflect potency observed in human blood, plasma, and serum

5	2018 ContraFect Corporation
©2016 ContraFect Corporation

CONFIDENTIAL